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Abstract
Background:   Activation of nuclear factor-κ B (NF-κ B) is one of the key events in early
atherosclerosis and restenosis. We hypothesized that tumor necrosis factor-α  (TNF-α ) induced
and NF-κ B mediated expression of intercellular adhesion molecule-1 (ICAM-1) can be inhibited by
antisense RelA p65 and NF-κ B1 p50 oligonucleotides (RelA p65 and NF-κ B1 p50).
Results:  Smooth muscle cells (SMC) from human coronary plaque material (HCPSMC, plaque
material of 52 patients), SMC from the human coronary media (HCMSMC), human endothelial cells
(EC) from umbilical veins (HUVEC), and human coronary EC (HCAEC) were successfully isolated
(HCPSMC, HUVEC), identified and cultured (HCPSMC, HCMSMC, HUVEC, HCAEC). 12 hrs prior
to TNF-α  stimulus (20 ng/mL, 6 hrs) RelA p65 and NF-κ B1 p50 (1, 2, 4, 10, 20, and 30 µM) and
controls were added for a period of 18 hrs. In HUVEC and HCAEC there was a dose dependent
inhibition of ICAM-1 expression after adding of both RelA p65 and NF-κ B1 p50. No inhibitory
effect was seen after incubation of HCMSMC with RelA p65 and NF-κ B1 p50. A moderate
inhibition of ICAM-1 expression was found after simultaneous addition of RelA p65 and NF-κ B1
p50 to HCPSMC, no inhibitory effect was detected after individual addition of RelA p65 and NF-
κ B1 p50.
Conclusions:  The data point out that differences exist in the NF-κ B mediated expression of
ICAM-1 between EC and SMC. Experimental antisense strategies directed against RelA p65 and
NF-κ B1 p50 in early atherosclerosis and restenosis are promising in HCAEC but will be confronted
with redundant pathways in HCMSMC and HCPSMC.
Introduction
Atherosclerosis is currently considered to be an exagger-
ated response of the vessel wall to injury characterized by
inflammation and fibrocellular proliferation [1]. This
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view is supported by the demonstration of abundant
macrophages and T lymphocytes in atherosclerotic
plaques that accumulate because of adhesion molecule
expression [2–4]. Nuclear factor-κ B (NF-κ B) regulates a
variety of genes coding for cytokines [5–9] and adhesion
receptors [8], that mediate endothelium-leukocyte adhe-
sion [10]. NF-κ B-regulated gene products such as inter-
leukin-lβ  (IL-1β ), monocyte chemoattractant protein-1
(MCP-1), tumor necrosis factor-α  (TNF-α ), and intercel-
lular adhesion molecule-1 (ICAM-1) have been found in
tissue specimens of atherosclerotic lesions [1]. Activated
NF-κ B was identified in smooth muscle cells (SMC),
macrophages, and endothelial cells (EC) of human
atherosclerotic tissue specimens [11], suggesting a
pathophysiologial role of NF-κ B in inflammatory and
proliferative processes in atherosclerosis [12]. Recently,
increased levels of NF-κ B were found in a clinical study
in humans with unstable angina pectoris [13].
The NF-κ B system might be a potential pharmacological
target to interfere with chemotactic and adhesive mech-
anisms within the vessel wall. The prototypic NF-κ B
dimer, consisting of the subunits RelA p65 and NF-κ B1
p50, is present in the cytosol in an inactive state, bound
to the inhibitory protein that are collectively termed Iκ B.
Activation of NF-κ B by a multitude of stimuli, including
inflammatory or lymphoproliferative cytokines, reactive
oxygen intermediates and micro-organisms, requires the
phosphorylation and proteolytic removal of Iκ B from the
dimeric complex. This is followed by an intermediate
translocation of activated NF-κ B to the nucleus, where
the dimer interacts with regulatory kb elements in pro-
moters and enhancers, thereby controlling inducible
gene transcription [8,14]. Recently first reports on inhib-
itory strategies of NF-κ B mediated activities in human
EC and SMC have been published [15–19].
ICAM-1 is one of various adhesion molecules that is acti-
vated via NF-κ B pathway. The expression of ICAM-1 by
SMC in human atheroma [20] and in hyperplastic le-
sions produced by experimental balloon injury [21] indi-
cates that augmented ICAM-1 expression constitutes a
marker of SMC activation of considerable in vivo rele-
vance. It has been demonstrated that TNF-α  increases
the expression of ICAM-1 in human arterial SMC from
peripheral [22] and coronary arteries [23,24] in a time
and dose dependent manner. Recently our laboratory
has reported [25] that high dose aspirin (5 mM) inhibits
expression of ICAM-1 in human coronary vascular cells.
In order to investigate a more specific inhibition of
ICAM-1 expression we analysed the effect of antisense
RelA p65 and NF-κ B1 p50 oligonucleotides on the NF-
κ B-mediated expression of ICAM-1.
Results
Intracellular uptake of FITC-labeled antisense
The intracellular uptake of fluorosense oligonucleotides
in HUVEC, HCAEC, HCMSMC (Fig. 1), and HCPSMC
was confirmed with fluorescence microscopy and flow
cytometry. After fluorescence microscopical examina-
tion of HUVEC, HCAEC, HCMSMC, and HCPSMC the
uptake of fluoresense started 1 hr after incubation. The
maximal uptake was reached after 8 hrs, this level was
kept for 24 and 48 hrs after incubation.
In flow cytometry examination baseline fluorescence was
2.77 in HUVEC, 4.18 in HCAEC, 1.88 in HCMSMC, and
4.68 in HCPSMC. 18 hrs after adding of fluorosense oli-
gonucleotides the fluorescence intensity was increased
to 82.03 and 89.11 in HUVEC and HCAEC (Fig. 2A,B),
respectively to 129.78 and 67.58 in HCMSMC and
HCPSMC (Fig. 2C,D).
Impact of antisense on TNF-α  mediated expression of 
ICAM-1 in HUVEC
Addition of antisense NF-κ B1 p50 oligonucleotide to
HUVEC caused only a very small inhibition of the TNF-α
induced expression of ICAM-1 (Fig. 4A). In HUVEC the
expression of ICAM-1 was 100, 93, and 91% after incuba-
tion with antisense NF-κ B1 p50 oligonucleotide in a con-
centration of 1, 2, and 4 µM/mL and 86, 91, and 93%
after incubation with antisense NF-κ B1 p50 oligonucle-
otide in a concentration of 10, 20, 30 µM/mL. Incubation
of HUVEC with antisense RelA p65 oligonucleotide
caused a moderate reduction of the expression of ICAM-
1 (Fig. 4A). Expression of ICAM-1 was 66, 71, and 75% af-
ter incubation with antisense RelA p65 oligonucleotide
in a concentration of 1, 2, and 4 µM/mL and 75, 89, 77%
after incubation with antisense RelA p65 oligonucleotide
Figure 1
Intracellular uptake of fluorosense oligonucleotides in
HCMSMC. Fluorescence microscopy, magnification ×  1625.BMC Molecular Biology 2001, 2:7 http://www.biomedcentral.com/1471-2199/2/7
in a concentration of 10, 20, and 30 µM/mL. Simultane-
ous adding of antisense RelA p65 and NF-κ B1 p50 oligo-
nucleotides to HUVEC caused a dose dependent
inhibition of the expression of ICAM-1. Expression of
ICAM-1 was 90, 80, 63, and 49% after incubation with
antisense RelA p65 and NF-κ B1 p50 oligonucleotides in
a concentration of 1, 2, 4 and 10 µM/mL. The further in-
crease of the concentration to 20 and 30 µM/mL did not
further increase the inhibitory effect. The expression of
ICAM-1 was 61% after incubation with 20 µM/mL and
53% after incubation with 30 µM/mL (Fig. 4A, Fig.
3A,B). Mismatched antisense RelA p65 and NF-κ B1 p50
oligonucleotides did not affect the expression of ICAM-1
in HUVEC, no matter whether added individually or si-
multaneously.
Impact of antisense on TNF-α  mediated expression of 
ICAM-1 in HCAEC
Addition of the oligonucleotide antisense NF-κ B1 p50 ol-
igonucleotides to cultures of HCAEC had no effect on the
expression of ICAM-1 in HCAEC (Fig. 4B). The expres-
sion of ICAM-1 was 102, 100, and 100% after incubation
with antisense NF-κ B1 p50 oligonucleotides in a concen-
tration of 1, 2, and 4 µM/mL and 95, 105, and 105% after
incubation with antisense NF-κ B1 p50 oligonucleotides
in a concentration of 10, 20, and 30 µM/mL. After addi-
tion of antisense RelA p65 oligonucleotides to cultures of
HCAEC the expression of ICAM-1 was moderately re-
duced. The expression of ICAM-1 was 65, 74, and 74% af-
ter incubation with antisense RelA p65 oligonucleotides
in a concentration of 1, 2, and 4 ×  µM/mL and 74, 79, and
82% after incubation with antisense RelA p65 oligonu-
cleotides in a concentration of 10, 20, and 30 µM/mL
(Fig. 4B). Simultaneous incubation of HCAEC with anti-
sense RelA p65 and NF-κ B1 p50 oligonucleotides inhib-
ited the expression of ICAM-1 in a strictly dose
dependent manner. The expression of ICAM-1 was 102,
83, and 85% after incubation with antisense RelA p65
and NF-κ B1 p50 oligonucleotides in a concentration of 1,
2, and 4 µM/mL and 70, 42, and 38% after incubation
with antisense RelA p65 and NF-κ B1 p50 oligonucle-
otides in a concentration of 10, 20, and 30 µM/mL (Fig.
4B, 3C,D). Mismatched antisense RelA p65 and NF-k-B1
p50 oligonucleotides did not affect the expression of
ICAM-1 in HCAEC, no matter whether added individual-
ly or simultaneously.
Impact of antisense on TNF-α  mediated expression of 
ICAM-1 in HCMSMC
In HCMSMC adding of antisense NF-κ B1 p50 oligonu-
cleotides caused a moderate increase of the expression of
TNF-α  induced expression of ICAM-1 (Fig. 4C). The ex-
pression of ICAM-1 was 117, 122, and 130% after incuba-
tion with antisense NF-κ B1 p50 oligonucleotides in a
concentration of 1, 2, and 4 µM/mL and 117, 113, and
135% after incubation with antisense NF-κ B1 p50 oligo-
nucleotides in a concentration of 10, 20, 30 µM/mL. An-
tisense RelA p65 oligonucleotides had a small inhibitory
effect on the expression of ICAM-1 in HCMSMC. The
only exception was the maximal concentration of anti-
sense RelA p65 oligonucleotides (30 µM/mL) with a
neutral effect. The expression of ICAM-1 was 81, 91, and
86% after incubation with antisense RelA p65 oligonu-
cleotides in a concentration of 1, 2, and 4 µM/mL. After
addition of antisense RelA p65 oligonucleotides in a con-
centration of 10 and 20 µM/mL the expression of ICAM-
1 was 86 and 81% (Fig. 4C). After adding of antisense
RelA p65 oligonucleotides in the maximal concentration
of 30 µM/mL no inhibitory effect on the surface expres-
sion of ICAM-1 was detected. Simultaneous incubation
of HCMSMC with antisense RelA p65 and NF-κ B1 p50
oligonucleotides caused a small stimulatory effect on the
expression of ICAM-1 in HCMSMC. The percentage of
HCMSMC with positive expression of ICAM-1 was 103,
100, and 110% after incubation with antisense RelA p65
Figure 2
Cytoflow-detection of intracellular FITC-labeled oligonucle-
otides 18 hrs after incubation: (A) HUVEC, (B) HCAEC, (C)
HCMSMC, (D) HCPSMC. Histogramms: x-axis = relative flu-
orescence, y-axis = cell number.BMC Molecular Biology 2001, 2:7 http://www.biomedcentral.com/1471-2199/2/7
and NF-κ B1 p50 oligonucleotides in a concentration of 1,
2, and 4 µM/mL and 110, 103, and 107% after incubation
with antisense RelA p65 and NF-κ B1 p50 oligonucle-
otides in a concentration of 10, 20, and 30 µM/mL (Fig.
4C). Mismatched antisense RelA p65 and NF-κ B1 p50 ol-
igonucleotides did not affect the expression of ICAM-1 in
HCMSMC, no matter whether added individually or si-
multaneously.
Impact of antisense on TNF-α  mediated expression of 
ICAM-1 in HCPSMC
Addition of antisense NF-κ B1 p50 oligonucleotides of
HCPSMC caused a small reduction of the expression of
ICAM-1 (Fig. 4D). The expression of ICAM-1 was 100,
92, and 90% after incubation with antisense NF-κ B1 p50
oligonucleotides in a concentration of 1, 2, and 4 µM/mL
and 90, 95, and 92% after incubation with antisense NF-
κ B1 p50 oligonucleotides in a concentration of 10, 20,
and 30 µM/mL. Incubation with antisense RelA p65 oli-
gonucleotides had a moderate stimulatory effect on the
expression of ICAM-1 (Fig. 4D). The expression of
ICAM-1 was 132, 129, and 113% after incubation with an-
tisense p65 oligonucleotides in a concentration of 1, 2,
and 4 µM/mL and 116, 129, and 107% after incubation
with antisense RelA p65 oligonucleotides in a concentra-
tion of 10, 20, and 30 µM/mL. Simultaneous adding of
antisense RelA p65 and NF-κ B1 p50 oligonucleotides to
HCPSMC had a dose dependent inhibitory effect on the
expression of ICAM-1. The expression of ICAM-1 was 88,
85, and 91% after incubation with antisense RelA p65
and NF-κ B1 p50 oligonucleotides in a concentration of 1,
2, and 4 µM/mL and 73, 73, and 70% after incubation
with antisense RelA p65 and NF-κ B1 p50 oligonucle-
otides in a concentration of 10, 20, and 30 µM/mL (Fig.
4D). Mismatched antisense RelA p65 and NF-κ B1 p50
oligonucleotides did not affect the expression of ICAM-1
in HCPSMC, no matter whether added individually or si-
multaneously.
Discussion
In this study we investigated the role of RelA p65 and
NF-κ B1 p50 for the TNF-α  mediated expression of
ICAM-1 in HUVEC and human coronary vascular cells.
The major findings of the study are: 1) intracellular up-
take of antisense RelA p65 and NF-κ B1 p50 oligonucle-
otides was confirmed by the detection of FITC-labeled
antisense RelA p65 and NF-κ B1 p50 oligonucleotides in
the intracellular space. 2) In HUVEC and HCAEC simul-
taneous incubation with antisense RelA p65 and NF-κ B1
p50 oligonucleotides caused a dose dependent inhibition
of ICAM-1 expression. The inhibitory effect was almost
doubled if compared to the effect after selective addition
of antisense RelA p65 oligonucleotides, selective incuba-
tion with antisense NF-κ B1 p50 oligonucleotides had no
effect. 3) Simultaneous incubation with antisense RelA
p65 and NF-κ B1 p50 oligonucleotides exhibited a mod-
erate inhibitory effect on expression of ICAM-1 in
HCPSMC but no effect in HCMSMC. No inhibitory effect
was seen after selective addition of antisense RelA p65
and NF-κ B1 p50 oligonucleotides to HCMSMC and
HCPSMC.
Figure 3
Effect of antisense Rel A p65 and NF-κ B1 p50 oligonucle-
otides on expression of ICAM-1 in HUVEC (B) and HCAEC
(D) in comparison to controls with mere TNF-α  stimulus
(HUVEC: A, HCAEC: C).
Figure 4
(A) Effect of antisense Rel A p65 and NF-κ B1 p50 oligonucle-
otides on expression of ICAM-1 α  in HUVEC, (B) HCAEC,
(C) HCMSMC, (D) HCPSMC. Graphic presentation of the
inhibitory effect in percent in relation to the stimulatory
effect of TNF-α .BMC Molecular Biology 2001, 2:7 http://www.biomedcentral.com/1471-2199/2/7
Effects of antisense p65 and p50 in HUVEC and HCAEC
Recently it has been reported that a decoy double-
stranded oligonucleotides containing a high affinity kb
sequence can specifically inhibit NF-κ B-dependent tran-
scription of gene products [29,30]. Lockyer et al. [15] and
Gawaz et al. [16] demonstrated that in HUVEC the ex-
pression of ICAM-1 can be inhibited via the adding of the
inhibitory protein Iκ B. The effect of antisense RelA p65
and NF-κ B1 p50 oligonucleotides to the expression of
adhesion molecules in cultures of HUVEC and HCAEC
has not yet been described. After adding simultaneously
antisense RelA p65 and NF-κ B1 p50 oligonucleotides the
expression of ICAM-1 in HUVEC and HCAEC was inhib-
ited in a dose dependent manner. The inhibitory effect
was almost 50% in HUVEC and even more than 40% in
HCAEC. The stronger effect in HCAEC can be partially
explained by the fact that the stimulatory effect of TNF-
α  is stronger in HCAEC in comparison to HUVEC [23].
Selective addition of mere antisense RelA p65 had a
moderate inhibitory effect, no effect was documented af-
ter selective adding of antisense NF-κ B1 p50. A predom-
inance of RelA p65 in the dimers of the NF-κ B complex
has already been suggested by Brand et al. [11]. The inhi-
bition of ICAM-1 expression in HUVEC and HCAEC after
simultaneous addition of antisense RelA p65 and NF-
κ B1 p50 was almost twice as high as the effect after addi-
tion of mere antisense RelA p65. Therefore it can be
speculated that a simultaneous administration of anti-
sense RelA p65 and NF-κ B1 p50 is necessary if a suffi-
cient inhibition of NF-κ B mediated activities shall be
achieved.
Effects of antisense p65 and p50 in HCMSMC and 
HCPSMC
Although many authors describe the activation of NF-κ B
in endothelial cells, relatively few data exist concerning
the activation of NF-κ B in SMC. Lawrence et al. [31]
demonstrated that bovine SMC exhibit basal, constitu-
tive NF-κ B activity in vitro, Cercek et al. [32] found an in-
creased activity of NF-κ B after balloon injury in rat
iliofemoral arteries. First investigations of NF-κ B activa-
tion in human arterial SMC were reported by Bourcier et
al. [33], Marayama [34], and Hishikawa et al. [17]. In an
earlier report we have demonstrated that the expression
of ICAM-1 in HCMSMC and HCPSMC is increased in a
time and dose dependent manner after treatment with
TNF-α  in a concentration of 2.5 – 20 ng/mL [23].
Recently Katsuyama et al. [35] reported that in rat vascu-
lar smooth muscle cells a strong inhibition of NF-κ B me-
diated effects can be achieved by dexamethasone or
aspirin. Only few groups investigated strategies to inhibit
activation of NF-κ B in human vascular SMC. Staels et al.
[18] reported that the activation of NF-κ B in human aor-
tic SMC can be inhibited by peroxisome proliferator-ac-
tivated alpha receptors (PPARalpha), Speir et al. [19]
demonstrated in HCMSMC that aspirin inhibits the cy-
tomegalo-virus-induced activation of NF-κ B.
The group of Hishikawa et al. [17] recently demonstrated
with electrophoretic mobility shift assays that in HCMS-
MC the TNF-α  induced activation of NF-κ B can be inhib-
ited by antisense RelA p65 and NF-κ B1 p50
oligonucleotides. If the NF-κ B system is sufficiently in-
hibited it should be expected that NF-κ B mediated ef-
fects are inhibited as well. In the study presented we
added antisense RelA p65 and NF-κ B1 p50 oligonucle-
otides to HCMSMC and HCPSMC and investigated the
expression of ICAM-1. However TNF-α  induced and NF-
κ B mediated expression of ICAM-1 was not inhibited in
HCMSMC, only a moderate inhibitory effect was seen in
HCPSMC. Different inhibitory effects in HCMSMC and
HCPSMC however are difficult to explain because the
stimulatory effect of TNF-a on the expression of ICAM-1
is almost equal in HCPSMC and HCMSMC [23]. Further-
more in HCPSMC no inhibitory effect was found after se-
lective addition of antisense RelA p65 or NF-κ B1 p50
oligonucleotides. Therefore it is likely that the moderate
inhibitory effect found after addition of antisense RelA
p65 and NF-κ B1 p50 oligonucleotides to HCPSMC is a
nonspecific effect.
Keeping in mind the negative effects in HCMSMC and
the non specific effects in HCPSMC it is allowed to spec-
ulate that in HCPSMC and HCMSMC activation of
ICAM-1 is triggered via different pathways, probably via
different members of the NF-κ B family [36]. This hy-
pothesis is supported by Lindner et al. [37] investigating
the role of the NF-κ B system after balloon catheter injury
in the rat carotid artery. Lindner and colleagues [37] re-
ported that in rat vascular SMC not only high levels of
NF-κ B1 p50 and RelA p65 but although high levels of
NF-κ B2 p52, c-Rel, and RelB were expressed.
Conclusions
The results point out that in HUVEC and HCAEC simul-
taneous antisense therapy with NF-κ B1 p50 and RelA
p65 oligonucleotids strongly inhibits activation NF-κ B
mediated expression of ICAM-1. After individual addi-
tion of antisense NF-κ B1 p50 and RelA p65 oligonucle-
otides to HUVEC and HCAEC only RelA p65 had an
inhibitory effect on TNF-α  mediated expression of
ICAM-1. However the superiority of the combined thera-
py was demonstrated by the fact that the inhibitory po-
tential was almost doubled after the simultaneous
therapy with RelA p65 and NF-κ B1 p50.
In HCMSMC and HCPSMC the negative or nonspecific
effects of antisense RelA p65 and NF-κ B1 p50 oligonu-
cleotides on TNF-α  mediated expression of ICAM-1 indi-BMC Molecular Biology 2001, 2:7 http://www.biomedcentral.com/1471-2199/2/7
cate the existence of redundant pathways. In further
studies it should be elucidated whether HCMSMC and
HCPSMC express other members of the NF-κ B family as
well, such as NF-κ B2 p52, c-Rel, and RelB. If these mol-
ecules are expressed in HCMSMC and HCPSMC, all of
these single pathways have to be blocked for a sufficient
inhibition of NF-κ B-related effects.
Materials and Methods
Cell isolation, identification, and cultivation
Endothelial cells (EC) were isolated from fresh human
umbilical cord veins (HUVEC) obtained after vaginal de-
livery by enzymatic disaggregation with collagenase/dis-
pase as previously described [26]. EC from human
coronary arteries (HCAEC) were purchased from Clonet-
ics-Bio Whittaker. HUVEC and HCAEC were identified
as EC by their by nonoverlapping cobblestone morphol-
ogy and by positive immunofluorescence with anti-von
Willebrand factor antibodies (Dakopatts, Hamburg, Ger-
many). EC were cultured in Endothelial Basal Medium
(EBM, Clonetics-Bio Whittaker), supplemented with bo-
vine brain extract (12 µg/mL), epidermal growth factor
(10 ng/mL), fcs (5%), gentamycin (50 µg/mL), ampho-
tericin (50 ng/mL), and hydrocortison (1 µg/mL). EC
were subcultured by trypsinization [26] and cells up to
passage 6 were used for the investigations. SMC from the
human coronary media (HCMSMC) were purchased
from Clonetics-Bio Whittaker (Venders, Belgium).
Atherosclerotic plaque material was extracted from cor-
onary arteries of 52 patients with a Simpson atherectomy
device. Immediately after extraction the specimens were
transferred to sterile glass flasks containing N-(2-hy-
droxyethyl)piper-N-(2-ethane sulfonic acid)-buffered
Dulbecco's modified Eagle medium (15 mM; Gibco, Egg-
enhausen, Germany) and transported within 3 h to the
cell culture laboratory. SMC from human coronary
plaque material (HCPSMC) were isolated with a colla-
genase/elastase enzyme mixture (Roche Diagnostics,
Mannheim, Germany) [27]. HCPSMC and HCMSMC
were confirmed as SMC by their typical "hill and valley"
growth pattern and their positive staining with antibod-
ies specific for smooth muscle α -actin (Progen, Heidel-
berg, Germany), as described [27]. HCPSMC and
HCMSMC were cultured in passage 2 and 3 in Smooth
Muscle Cell Basal Medium (SmBM, Clonetics-Bio Whit-
taker), supplemented with 5% fetal calf serum (fcs), insu-
lin (5 µg/mL), fibroblast growth factor (2 ng/mL),
epidermal growth factor (0,5 ng/mL), gentamycin (50
mg/mL), and amphotericin (50 ng/mL).
All cell incubations were done at 37°C in a humidified at-
mosphere of air containing 5% C02. Tissues were collect-
ed with the patients' informed consent and approval by
the Ethical Committee of the University of Ulm.
Oligonucleotides
Intracellular uptake of oligonucleotides was tested with
fluorescence microscopy and flow cytometry investiga-
tions. For fluorescence microscopy HUVEC, HCAEC,
HCMSMC, and HCPSMC were seeded on 16-well dishes
on glass slides (Nalge-Nunc, Hamburg, Germany) in a
density of 2–3 ×  103 Zellen ×  cm-2. Cells were incubated
with fluorescein-labeled antisense oligonucleotides
(fluorosense; form: phosphothioate DNA-Na-salt dilut-
ed with oligo-buffer) for a period of 1, 2, 4, 8, 24, and 48
hrs with a stock solution (5 nmol/5 µl; Biognostik, Göt-
tingen, Germany). For the investigations an immunoflu-
orescence microscope was used.
For flow cytometry investigations 2 ×  105 HUVEC,
HCAEC, HCMSMC, and HCPSMC were seeded in petri
dishes (28 cm2) and the stock solution was added for a
period of 18 hrs to the cultures. After 18 hrs cells were
washed twice with PBS, detached by trypsin treatment,
and suspended in phosphate-buffered saline, pH 7.2,
containing 1% of bovine serum albumin (BSA) with 0.2%
of sodium azide at 4°C. This buffer was used in all subse-
quent steps. Cells (100% gated) were analyzed immedi-
ately with a fluorescence-activated cell sorter (FACScan,
Becton Dickinson, Heidelberg, Germany, Macintosh
System Software 7.1.0).
Antisense RelA p65 and NF-κ B1 p50 oligonucleotides is
the revise complement of a target sequence as described
by Ruben et al. [28]. The form is a phosphothioate DNA-
Na-salt, lyophilized and diluted with oligo-buffer (Biog-
nostik). Antisense RelA p65 and NF-κ B1 p50 oligonucle-
otides are added for a period of 18 hrs in a concentration
of, 1, 2, 4, 10, 20, and 30 µM. As controls mismatched an-
tisense RelA p65 and NF-κ B1 p50 oligonucleotides were
used. Form and concentration is identical as described
for antisense RelA p65 and NF-κ B1 p50 oligonucleotides.
TNF-α  induced expression of ICAM-1
Surface expression of ICAM-1 was investigated with indi-
rect immunofluorescence microscopy. HUVEC, HCAEC,
HCMSMC, and HCPSMC were seeded on round cover-
slips into 6-well plates (Falcon/Becton-Dickinson, Hei-
delberg, Germany). 18 hrs before fixation in 4%
paraformaldehyde antisense RelA p65 and NF-κ B1 p50
oligonucleotides and mismatched controls were added, 6
hrs before fixation cultures were stimulated with recom-
binant human TNF-α  (20 ng/mL; Sigma, Deisenhofen,
Germany). Human ICAM-1 was detected using mono-
clonal anti-ICAM-1 antibodies (clone 84H10, 2 µg/mL,
Dianova Immunotech, Hamburg, Germany). Tetrarhod-
amine-isothiocyanate (TRITC)-labeled secondary anti-
bodies were purchased from Dianova Immunotech. In
100 cells the expression of ICAM-1 was analysed in du-
plicate by two independent observers according the cri-BMC Molecular Biology 2001, 2:7 http://www.biomedcentral.com/1471-2199/2/7
teria negative, low and strong. Since both low and
negative staining were found as basic expression of
ICAM-1 in untreated controls, only a strong positive
staining was rated as positive expression of ICAM-1. The
inhibitory effect of antisense RelA p65 and NF-κ B1 p50
oligonucleotides was calculated in relation to the relative
stimulatory effect of TNF-α . For the investigations an
immunofluorescence microscope was used (100 cell per
concentration, magnification ×  100).
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